Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Biogen Idec receives negative opinion from the CHMP on Fampyra
B cells and multiple sclerosis.
Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies: A Comparative Study.
Natalizumab Use During the Third Trimester of Pregnancy.
Emotional Change-Associated T Cell Mobilization at the Early Stage of a Mouse Model of Multiple Sclerosis.
Intermittent self-catheterisation in MS.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Receptos reports third quarter 2013 financial results
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
Change in the clinical development program for laquinimod
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Patient reported outcome measures in neurogenic bladder.

Pages